ACON | Jotup

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on:

Monday, March 4, 2024

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points:

Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
We look forward to introducing Nociscan to a growing number of physicians and patients.”
Access to the publication can be found here.

Aclarion Announces Closing of $3.0 Million Public Offering

Retrieved on:

Tuesday, February 27, 2024

Algorithm, Prospectus, ACON, Register, Physician, Sale, Form, Biomarker, CO, Security (finance)

Each unit was sold at a public offering price of $0.58.

Key Points:

Each unit was sold at a public offering price of $0.58.
The common warrants are immediately exercisable at a price of $0.58 per share and expire five years from the date of issuance.
Gross proceeds, before deducting placement agent fees and other offering expenses, are approximately $3.0 million.
The offering was made only by means of a prospectus which is a part of the Registration Statement.

Aclarion Announces Pricing of $3.0 Million Public Offering

Retrieved on:

Monday, February 26, 2024

Algorithm, Prospectus, ACON, Register, Physician, Sale, Form, Biomarker, CO, Security (finance)

Each unit is being sold at a public offering price of $0.58.

Key Points:

Each unit is being sold at a public offering price of $0.58.
The common warrants will be immediately exercisable at a price of $0.58 per share and will expire five years from the date of issuance.
Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.0 million.
The offering is being made only by means of a prospectus which is a part of the Registration Statement.

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Retrieved on:

Monday, February 5, 2024

Partnership, CO, Surgeon, FACS, CLARITY, Biomedicine, Biomarker, Patient, ACON, Physician, Biomedical engineering, Algorithm, KOL, Johns Hopkins, Medical device

BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed several recent financing transactions that have significantly reduced debt and increased available cash. The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.

Key Points:

The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.
The Company believes these recent financing transactions were on terms more favorable than those available in the public capital markets.
The Company expects to add 5 new KOLs to the Nociscan network in the first half of 2024.
The Company will provide updates as clinical sites are added to CLARITY and KOLs are onboarded through the strategic partnership.

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Retrieved on:

Monday, January 22, 2024

Biomarker, Research, ACON, Diagnosis, Low back pain, Software as a service, CO, Algorithm, Spine, Division, Neurosurgery, Barrow Neurological Institute, Pain, Opioid, Magnetic resonance imaging, Education, United, Physician

BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.

Key Points:

Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease.
Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain.
Uribe is a renowned neurosurgeon at one of the world’s leading neurological institutes, Barrow,” said Ryan Bond, Chief Strategy Officer of Aclarion.
For information about Nociscan use in Phoenix, please contact Aclarion at [email protected] .

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Retrieved on:

Wednesday, January 17, 2024

Patient, MRI, ACON, Intelligence, CO, Algorithm, Low back pain, Magnetic resonance imaging, Biomarker, Surgeon, Physician, Medical imaging

BROOMFIELD, CO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (cLBP), announced today the product release of Nociscan 2.6 which includes support for additional leading magnetic resonance imaging (MRI) scanners. With this product release Nociscan can now be performed on MRI machines beyond those manufactured by Siemens.

Key Points:

With this product release Nociscan can now be performed on MRI machines beyond those manufactured by Siemens.
“This important technical milestone expands Nociscan access to healthcare providers and patients throughout the world in a very significant way,” stated Brent Ness, CEO of Aclarion.
MRI compatibility with Nociscan has been historically limited to machines manufactured by Siemens.
Although Siemens is a major player in the MRI market, we will not rest until Nociscan is available on the leading MRI machines of all manufacturers.

Novipax Announces Strategic Partnership with Front1 Health Partners to Revolutionize Operating Room Safety and Efficiency

Retrieved on:

Monday, January 22, 2024

Novipax, a leading US-based manufacturer of high-quality absorbent pads, is excited to announce a groundbreaking partnership with Front1 Health Partners, a pioneer in healthcare solutions.

Key Points:

Novipax, a leading US-based manufacturer of high-quality absorbent pads, is excited to announce a groundbreaking partnership with Front1 Health Partners, a pioneer in healthcare solutions.
Through this partnership, Novipax leveraged its industry-leading expertise in absorbent technologies to produce a bespoke line of absorbent mats under Front1 Health Partners’ private label.
Katelyn Doepel, CEO of Front1 Health Partners added, “The collaboration with Novipax is a strategic step towards enhancing our product offerings.
Front1 Health Partners is focused on strategies and solutions to improve the bottom line goals of health systems across the United States.

Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

Retrieved on:

Monday, January 8, 2024

EOS, Partnership, ACON, Physician, Biomarker, Pain, Software as a service, Surgeon, CO, LOI, Spine, Patient, Algorithm, ATEC, KOL, Pharmaceutical industry

BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent (“LOI”) with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

Key Points:

That platform will be designed to improve clinical outcomes, while reducing overall procedural costs for patients with chronic low back pain (cLBP).
The agreement memorializes a multi-step strategic partnership in which ATEC and Aclarion have committed to work together to identify key opinion leader (KOL) surgeons to evaluate the Nociscan technology.
As positive synergies emerge, ATEC and Aclarion intend to co-market Nociscan in targeted markets.
In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion has agreed to provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

Aclarion Announces Reverse Stock Split

Retrieved on:

Tuesday, January 2, 2024

Transfer, ACON, State, Physician, CUSIP, CO, Letter, Biomarker, Algorithm, Exercise, Security (finance)

The reverse stock split will not change the authorized number of shares of the Company’s common stock.

Key Points:

The reverse stock split will not change the authorized number of shares of the Company’s common stock.
The reverse stock split will apply to the Company’s outstanding warrants, stock options and restricted stock units.
The number of shares of common stock into which these outstanding securities are convertible or exercisable will be adjusted proportionately as a result of the reverse stock split.
Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-16 reverse stock split.

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Retrieved on:

Monday, November 27, 2023

Neck pain, ACON, Physician, Software as a service, DCLP, CO, University, Patent, Biomarker, US1, Patient, Intelligence, Algorithm, Medical imaging

BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed 1,000 commercial Nociscan exams.

Key Points:

“The milestone by itself is significant, but the pace of our commercial adoption is the most exciting aspect of achieving 1,000 commercial scans,” stated Brent Ness, CEO of Aclarion.
“For context, 36% of these 1,000 studies were done in the past 12 months, demonstrating the adoption our strategy has produced along our journey to standard of care.
This is an important commercial milestone for our physician customers, their patients, and our team.”
266 million people worldwide suffer from degenerative spine disease and low back pain1.
Nociscan is currently available at imaging facilities utilizing select model Siemens 1.5T and 3T magnetic resonance spectroscopy.